Search

for
Search:

Research

5 / 1000+ results

research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects

17 citations , June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology”

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

research PNU 157706, a novel dual type I and II5α-reductase inhibitor

42 citations , February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology”

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

research Immunohistochemical localization of types 1 and 2 5α-reductase in human scalp

100 citations , September 1999 in “British Journal of Dermatology”

This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.

research Effect of C-ring modifications in benzo[c]quinolizin-3-ones, new selective inhibitors of human 5α-reductase 1

12 citations , June 2001 in “Bioorganic & Medicinal Chemistry”

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

research Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-Reductase: evidence for mechanism-Based inhibition by finasteride

25 citations , September 1998 in “The Journal of Steroid Biochemistry and Molecular Biology”

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

View more "human recombinant 5ar type 1" in research →

Community Join

1 / 1000+ results

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 2 years ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

View more "human recombinant 5ar type 1" in community →